Cancer Risk with Xeljanz, Other JAK Inhibitors Higher Than Among Users of Older TNF Inhibitors
Side effects of Xeljanz, Rinvoq, Olumiant and Other Janus Kinase (JAK) inhibitors linked to higher cancer risk than TNF inhibitors, like Humira and Enbrel